CD8 T Cell–Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas

Murphy, Katherine; Griffith, Thomas

doi:10.3390/cancers8080071

Cited by 11Glioma Diagnosis and TreatmentCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

CD8 T Cell–Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas

Open access

Murphy, Katherine, Griffith, Thomas·2016·Cancers

DOI 10.3390/cancers8080071PMC PMC4999780

Open this paper in CoChat — free account Open PDF

Abstract

Malignant brain tumors continue to represent a devastating diagnosis with no real chance for cure. Despite an increasing list of potential salvage therapies, standard-of-care for these patients has not changed in over a decade. Immunotherapy has been seen as an exciting option, with the potential to offer specific and long lasting tumor clearance. The “gold standard” in immunotherapy has been the development of a tumor-specific CD8 T cell response to potentiate tumor clearance and immunological memory. While many advances have been made in the field of immunotherapy, few therapies have seen true success. Many of the same principles used to develop immunotherapy in tumors of the peripheral organs have been applied to brain tumor immunotherapy. The immune-specialized nature of the brain should call into question whether this approach is appropriate. Recent results from our own experiments require a rethinking of current dogma. Perhaps a CD8 T cell response is not sufficient for an organ as immunologically unique as the brain. Examination of previously elucidated principles of the brain’s immune-specialized status and known immunological preferences should generate discussion and experimentation to address the failure of current therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3390/cancers8080071

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Treg cells functionally repress the tumor-killing activity of CD8+ T cells through various activities, including TGF-β1 activation.
“These then functionally repress, through various activities, including TGF-β1 activation82,145, the tumor-killing activity of CD8+ T cells 58,63,82,145,218,219”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [218]
Treg cells contribute to macrophage and neutrophil polarization towards a regenerative rather than inflammatory cell state.
“and contribute to macrophage and neutrophil polarization towards a regenerative rather than inflammatory cell state58,63,82,145,172,173,218,219.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [218]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
Ostrom, Q. T., Gittleman, H. R., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C. A., & Barnholtz‐Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 12,049 · see citing works
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,667 · see citing works
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · see citing works
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · see citing works
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · see citing works
Structural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413 · see citing works
Malignant Gliomas in Adults
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 4,201 · see citing works
NITRIC OXIDE AND MACROPHAGE FUNCTION
MacMicking, J. D., Xie, Q. W., & Nathan, C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.323 · Cited by 4,184 · see citing works
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,023 · see citing works
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L. E., Worthen, G. S., & Albelda, S. Μ. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,382 · see citing works
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823 · see citing works
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767 · see citing works
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · see citing works
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,382 · see citing works
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345 · see citing works
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance
Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., & Sakaguchi, S. (2002) · Nature Immunology · doi:10.1038/ni759 · Cited by 1,729 · see citing works
The B7–CD28 superfamily
Sharpe, A. H., & Freeman, G. J. (2002) · Nature reviews. Immunology · doi:10.1038/nri727 · Cited by 1,719 · see citing works
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011
Ostrom, Q. T., Gittleman, H. R., Liao, P., Rouse, C. D., Chen, Y., Dowling, J., Wolinsky, Y., Kruchko, C. A., & Barnholtz‐Sloan, J. S. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou223 · Cited by 1,718 · see citing works
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,678 · see citing works
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C.-H., Morgan, R. A., & Dudley, M. E. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2355 · Cited by 1,654 · see citing works
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345 · see citing works
Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye.
Medawar, P. B. (1948) · PubMed · Cited by 1,084 · see citing works
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079 · see citing works
Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
Zeng, J., See, A. P., Phallen, J., Jackson, C. M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T. J., Albesiano, E., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.12.025 · Cited by 889 · see citing works
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., Mitchell, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6963 · Cited by 808 · see citing works
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Brown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W.-C., Naranjo, A., Starr, R., Wagner, J. R., Wright, C. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0428 · Cited by 766 · see citing works
Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomas
Komohara, Y., Ohnishi, K., Kuratsu, J., & Takeya, M. (2008) · The Journal of Pathology · doi:10.1002/path.2370 · Cited by 738 · see citing works
The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses
Deeken, J. F., & Löscher, W. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2854 · Cited by 723 · see citing works
Temozolomide and treatment of malignant glioma.
Friedman, H. S., Kerby, T., & Calvert, H. (2000) · PubMed · Cited by 722 · see citing works
A vaccine targeting mutant IDH1 induces antitumour immunity
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., Menn, O., Osswald, M., Oezen, I., Ott, M., et al. (2014) · Nature · doi:10.1038/nature13387 · Cited by 707 · see citing works
Tumor-Associated Neutrophils: New Targets for Cancer Therapy
Gregory, A. D., & Houghton, A. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2583 · Cited by 707 · see citing works
Tumor-associated neutrophils: friend or foe?
Fridlender, Z. G., & Albelda, S. Μ. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs123 · Cited by 699 · see citing works
NK cell-based immunotherapy for malignant diseases
Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.10 · Cited by 631 · see citing works
Diffuse glioma growth: a guerilla war
Claes, A., Idema, A. J. S., & Wesseling, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0293-7 · Cited by 627 · see citing works
The interaction of anticancer therapies with tumor-associated macrophages
Mantovani, A., & Allavena, P. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150295 · Cited by 617 · see citing works
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses1
Hussain, S. F., Yang, D., Suki, D., Aldape, K., Grimm, E., & Heimberger, A. B. (2006) · Neuro-Oncology · doi:10.1215/15228517-2006-008 · Cited by 592 · see citing works
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Berghoff, A. S., Kiesel, B., Widhalm, G., Rajky, O., Ricken, G., Wöehrer, A., Dieckmann, K. U., Filipits, M., Brandstetter, A., Weller, M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou307 · Cited by 587 · see citing works
Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells
Lechner, M. G., Liebertz, D. J., & Epstein, A. L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000901 · Cited by 582 · see citing works
Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Wainwright, D. A., Chang, A. L., Dey, M., Balyasnikova, I. V., Kim, C. K., Tobias, A. L., Cheng, Y., Kim, J. W., Qiao, J., Zhang, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0514 · Cited by 571 · see citing works
Induction of CD8+T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma
Okada, H., Kaliński, P., Ueda, R., Hoji, A., Kohanbash, G., Donegan, T. E., Mintz, A. H., Engh, J. A., Bartlett, D. L., Brown, C. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7744 · Cited by 570 · see citing works
Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment
Liau, L. M., Prins, R. M., Kiertscher, S. M., Odesa, S. K., Kremen, T. J., Giovannone, A. J., Lin, J., Chute, D. J., Mischel, P. S., Cloughesy, T. F., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0464 · Cited by 543 · see citing works
Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.
Yu, J. S., Wheeler, C. J., Zeltzer, P. M., Ying, H., Nacis-Finger, D., Lee, P.-K., Yong, W. H., Incardona, F., Thompson, R. C., Riedinger, M. S., et al. (2001) · PubMed · Cited by 513 · see citing works
Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAIL
Griffith, T. S., Wiley, S. R., Kubin, M. Z., Sedger, L. M., Maliszewski, C. R., & Fanger, N. A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.8.1343 · Cited by 477 · see citing works
Self-citation
Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
Johnson, L. A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P. R., McGettigan, S. E., Nace, A., Dentchev, T., Thekkat, P. U., Loew, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4963 · Cited by 452 · see citing works
Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy
Prins, R. M., Soto, H., Konkankit, V., Odesa, S. K., Eskin, A., Yong, W. H., Nelson, S. F., & Liau, L. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2563 · Cited by 448 · see citing works
Robust tumor immunity to melanoma mediated by interleukin-9–producing T cells
Purwar, R., Schlapbach, C., Xiao, S., Kang, H. S., Elyaman, W., Jiang, X., Jetten, A. M., Khoury, S. J., Fuhlbrigge, R. C., Kuchroo, V. K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2856 · Cited by 442 · see citing works
CD4 cells can be more efficient at tumor rejection than CD8 cells
Pérez‐Díez, A., Joncker, N. T., Choi, K., Chan, W. F. N., Anderson, C. C., Lantz, O. J., & Matzinger, P. (2007) · Blood · doi:10.1182/blood-2006-10-051318 · Cited by 436 · see citing works
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
Reardon, D. A., Gokhale, P. C., Klein, S. R., Ligon, K. L., Rodig, S. J., Ramkissoon, S. H., Jones, K. L., Conway, A. S., Liao, X., Zhou, J. M., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0151 · Cited by 433 · see citing works
Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR
Valzasina, B., Guiducci, C., Dislich, H., Killeen, N. P., Weinberg, A. D., & Colombo, M. P. (2005) · Blood · doi:10.1182/blood-2004-07-2959 · Cited by 428 · see citing works
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
Phuphanich, S., Wheeler, C. J., Rudnick, J. D., Mazer, M., Wang, H., Nuño, M., Richardson, J., Fan, X., Ji, J., Chu, R. M., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1319-0 · Cited by 386 · see citing works
HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors
Ahmed, N. M., Salsman, V. S., Kew, Y., Shaffer, D. R., Powell, S. Z.-E., Zhang, Y. J., Grossman, R. G., Heslop, H. E., & Gottschalk, S. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1322 · Cited by 382 · see citing works
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40
Sugamura, K., Ishii, N., & Weinberg, A. D. (2004) · Nature reviews. Immunology · doi:10.1038/nri1371 · Cited by 333 · see citing works
Primary T Cell Expansion and Differentiation In Vivo Requires Antigen Presentation by B Cells
Crawford, A., MacLeod, M. K. L., Schumacher, T. N., Corlett, L., & Gray, D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3498 · Cited by 311 · see citing works
Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma
Morgan, R. A., Johnson, L. A., Davis, J. L., Zheng, Z., Woolard, K., Reap, E. A., Feldman, S. A., Chinnasamy, N., Kuan, C.-T., Song, H., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.041 · Cited by 306 · see citing works
Neutrophils Promote the Malignant Glioma Phenotype through S100A4
Liang, J., Piao, Y., Holmes, L., Fuller, G. N., Henry, V. K., Tiao, N., & de Groot, J. F. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1279 · Cited by 277 · see citing works
The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity
Wang, R.-F. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)01896-8 · Cited by 268 · see citing works
Effects of treatment on long‐term survivors with malignant astrocytomas
Imperato, J. P., Paleologos, N. A., & Vick, N. A. (1990) · Annals of Neurology · doi:10.1002/ana.410280614 · Cited by 254 · see citing works
Intratumoral Injection of CpG Oligonucleotides Induces the Differentiation and Reduces the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells
Shirota, Y., Shirota, H., & Klinman, D. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101304 · Cited by 254 · see citing works
CONDITIONS DETERMINING THE TRANSPLANTABILITY OF TISSUES IN THE BRAIN
Murphy, J. B., & Sturm, E. (1923) · Journal of Experimental Medicine · doi:10.1084/jem.38.2.183 · Cited by 246 · see citing works
T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma
Chow, K. K. H., Naik, S., Kakarla, S., Brawley, V. S., Shaffer, D. R., Yi, Z., Rainusso, N. C., Wu, M.-F., Liu, H., Kew, Y., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.210 · Cited by 241 · see citing works
CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Zoglmeier, C., Bauer, H., Noerenberg, D., Wedekind, G., Bittner, P. M., Sandholzer, N., Rapp, M., Anz, D., Endres, S., & Bourquin, C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2672 · Cited by 238 · see citing works
Neutrophil infiltration into human gliomas
Fossati, G., Ricevuti, G., Edwards, S. W., Walker, C. A., Dalton, A., & Rossi, M. (1999) · Acta Neuropathologica · doi:10.1007/s004010051093 · Cited by 226 · see citing works
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy
Dutoit, V., Herold-Mende, C., Hilf, N., Schoor, O., Beckhove, P., Bucher, J., Dorsch, K., Flohr, S., Fritsche, J., Lewandrowski, P., et al. (2012) · Brain · doi:10.1093/brain/aws042 · Cited by 201 · see citing works
Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma
Sayour, E. J., McLendon, P., McLendon, R., De Leon, G., Reynolds, R., Kresak, J., Sampson, J. H., & Mitchell, D. A. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1651-7 · Cited by 196 · see citing works
Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain
Zagzag, D., Salnikow, K., Chiriboga, L. A., Yee, H. T., Lan, L., Ali, M., Garcia, R., Demaria, S., & Newcomb, E. W. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700233 · Cited by 191 · see citing works
Late Effects of Therapy for Pediatric Brain Tumor Survivors
Turner, C. D., Rey‐Casserly, C. M., Liptak, C. C., & Chordas, C. A. (2009) · Journal of Child Neurology · doi:10.1177/0883073809341709 · Cited by 191 · see citing works
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors
Sampson, J. H., Alexander, L. E. C., Lee, S., Archer, G. E., Ashley, D. M., Wikstrand, C. J., Hale, L. P., Small, C. G., Dranoff, G., Friedman, A. H., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130166597 · Cited by 188 · see citing works
Mast cells as targets for immunotherapy of solid tumors
Oldford, S. A., & Marshall, J. S. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.02.020 · Cited by 179 · see citing works
Highly Activated Cytotoxic CD8 T Cells Express Protective IL-10 at the Peak of Coronavirus-Induced Encephalitis
Trandem, K., Zhao, J., Fleming, E., & Perlman, S. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003292 · Cited by 158 · see citing works
A Critical Role for Mast Cells and Mast Cell-Derived IL-6 in TLR2-Mediated Inhibition of Tumor Growth
Oldford, S. A., Haidl, I. D., Howatt, M., Leiva, C., Johnston, B., & Marshall, J. S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001137 · Cited by 148 · see citing works
Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor–Modified T Cells
Kong, S., Sengupta, S., Tyler, B., Bais, A. J., Ma, Q., Doucette, S., Zhou, J., Sahin, A., Carter, B. S., Brem, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0319 · Cited by 135 · see citing works
Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010
Gittleman, H. R., Ostrom, Q. T., Rouse, C. D., Dowling, J., de Blank, P. M. K., Kruchko, C. A., Elder, J. B., Rosenfeld, S. S., Selman, W. R., Sloan, A. E., et al. (2014) · Cancer · doi:10.1002/cncr.29015 · Cited by 135 · see citing works
Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation1This work was supported by National Institute of Health Grant (RO1 NS33070-03) and The Brain Tumor Society.1
Harling‐Berg, C. J., Park, J. T., & Knopf, P. M. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00130-7 · Cited by 134 · see citing works
Cytolytic CD4 + T cells in viral immunity
Soghoian, D. Z., & Streeck, H. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.132 · Cited by 133 · see citing works
Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas
Okada, H., Lieberman, F. S., Walter, K. A., Lunsford, L. D., Kondziolka, D. S., Bejjani, G. K., Hamilton, R. L., Torres-Trejo, A., Kaliński, P., Cai, Q., et al. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-67 · Cited by 130 · see citing works
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO
Wainwright, D. A., Dey, M., Chang, A. L., & Lesniak, M. S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00116 · Cited by 128 · see citing works
Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology
Yang, I., Han, S. J., Sughrue, M. E., Tihan, T., & Parsa, A. T. (2011) · Journal of neurosurgery · doi:10.3171/2011.4.jns101172 · Cited by 127 · see citing works
EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma
Miao, H., Choi, B. D., Suryadevara, C. M., Sanchez-Perez, L. A., Yang, S., Leon, G. D., Sayour, E. J., McLendon, R. E., Herndon, J. E., Healy, P. N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094281 · Cited by 124 · see citing works
B Cells Are Critical to T-cell—Mediated Antitumor Immunity Induced by a Combined Immune-Stimulatory/Conditionally Cytotoxic Therapy for Glioblastoma
Candolfi, M., Curtin, J. F., Yagiz, K., Assi, H. H., Wibowo, M., Alzadeh, G. E., Foulad, D. S., Muhammad, A. G., Salehi, S., Keech, N., et al. (2011) · Neoplasia · doi:10.1593/neo.11024 · Cited by 116 · see citing works
Cyclophosphamide Promotes Chronic Inflammation–Dependent Immunosuppression and Prevents Antitumor Response in Melanoma
Sevko, A., Sade-Feldman, M., Kanterman, J., Michels, T., Falk, C. S., Umansky, L., Ramacher, M., Kato, M., Schadendorf, D., Baniyash, M., et al. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.444 · Cited by 111 · see citing works
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer
Péré, H., Tanchot, C., Bayry, J., Terme, M., Taı̈eb, J., Badoual, C., Adotévi, O., Merillon, N., Marcheteau, E., Quillien, V., et al. (2012) · OncoImmunology · doi:10.4161/onci.18852 · Cited by 105 · see citing works
Overview of Cellular Immunotherapy for Patients with Glioblastoma
Vauléon, É., Avril, T., Collet, B., Mosser, J., & Quillien, V. (2010) · Journal of Immunology Research · doi:10.1155/2010/689171 · Cited by 98 · see citing works
RESIDUAL FUNCTION FOLLOWING HEMISPHERECTOMY FOR TUMOUR AND FOR INFANTILE HEMIPLEGIA
Gardner, W. J., Karnosh, L. J., McCLURE, C. C., & GARDNER, A. K. (1955) · Brain · doi:10.1093/brain/78.4.487 · Cited by 90 · see citing works
Current Vaccine Trials in Glioblastoma: A Review
Xu, L. W., Chow, K. K. H., Lim, M. K., & Li, G. (2014) · Journal of Immunology Research · doi:10.1155/2014/796856 · Cited by 87 · see citing works
Mast Cell Accumulation in Glioblastoma with a Potential Role for Stem Cell Factor and Chemokine CXCL12
Põlajeva, J., Sjösten, A., Lager, N., Kastemar, M., Waern, I., Alafuzoff, I. I., Smits, A., Westermark, B., Pejler, G., Uhrbom, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025222 · Cited by 81 · see citing works
OX40 costimulation can abrogate Foxp3+ regulatory T cell‐mediated suppression of antitumor immunity
Kitamura, N., Murata, S., Ueki, T., Mekata, E., Reilly, R. T., Jaffee, E. M., & Tani, T. (2009) · International Journal of Cancer · doi:10.1002/ijc.24435 · Cited by 81 · see citing works
Ovalbumin is more immunogenic when introduced into brain or cerebrospinal fluid than into extracerebral sites
Gordon, L. B., Knopf, P. M., & Cserr, H. F. (1992) · Journal of Neuroimmunology · doi:10.1016/0165-5728(92)90215-7 · Cited by 79 · see citing works
Multiple HLA Class II-Restricted Melanocyte Differentiation Antigens Are Recognized by Tumor-Infiltrating Lymphocytes from a Patient with Melanoma
Robbins, P. F., El‐Gamil, M., Li, Y. F., Zeng, G., Dudley, M. E., & Rosenberg, S. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.6036 · Cited by 78 · see citing works
Autoantibodies against GLEA2 and PHF3 in glioblastoma: Tumor‐associated autoantibodies correlated with prolonged survival
Pallasch, C. P., Struss, A.-K., Munnia, A., König, J., Steudel, W.-I., Fischer, U., & Meese, E. U. (2005) · International Journal of Cancer · doi:10.1002/ijc.20929 · Cited by 75 · see citing works
In Vivo Vaccination With Tumor Cell Lysate Plus CpG Oligodeoxynucleotides Eradicates Murine Glioblastoma
Wu, A., Oh, S., Gharagozlou, S., Vedi, R. N., Ericson, K., Low, W. C., Chen, W., & Ohlfest, J. R. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318155a0f6 · Cited by 73 · see citing works
Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment.
Sharabi, A. B., Tran, P. T., Lim, M. K., Drake, C. G., & DeWeese, T. L. (2015) · PubMed · Cited by 72 · see citing works
NK and CD4 Cells Collaborate to Protect against Melanoma Tumor Formation in the Brain
Prins, R. M., Vo, D. D., Khan-Farooqi, H., Yang, M., Soto, H., Economou, J. S., Liau, L. M., & Ribas, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8448 · Cited by 63 · see citing works
Is the Brain "An Immunologically Privileged Site?"
Scheinberg, L. C. (1966) · Archives of Neurology · doi:10.1001/archneur.1966.00470130066006 · Cited by 55 · see citing works
Interferon-gamma in Brain Tumor Immunotherapy
Kane, A. J., & Yang, I. (2009) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2009.08.011 · Cited by 50 · see citing works
Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity
Gordon, L. B., Nolan, S. C., Cserr, H. F., Knopf, P. M., & Harling‐Berg, C. J. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.5.2399 · Cited by 46 · see citing works
Ipilimumab (Yervoy) and the TGN1412 catastrophe
Bakács, T., Mehrishi, J. N., & Moss, R. W. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.07.005 · Cited by 41 · see citing works
Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond
Riddell, S. R., Jensen, M. C., & June, C. H. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.10.021 · Cited by 40 · see citing works
Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
Ahn, B. J., Pollack, I., & Okada, H. (2013) · Cancers · doi:10.3390/cancers5041379 · Cited by 38 · see citing works
CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma
James, B. R., Anderson, K. G., Brincks, E. L., Kucaba, T. A., Norian, L. A., Masopust, D., & Griffith, T. S. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1598-8 · Cited by 37 · see citing works
Self-citation
An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas
Murphy, K. A., Lechner, M. G., Popescu, F. E., Bedi, J., Decker, S. A., Hu, P., Erickson, J. R., O’Sullivan, M. G., Swier, L. E., Salazar, A. Μ., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0990 · Cited by 37 · see citing works
Self-citation
Normal cerebrospinal fluid suppresses the in vitro development of cytotoxic T cells: Role of the brain microenvironment in CNS immune regulation1This work was supported by research grants from the American Cancer Society (IRG 45-36), the National Institutes of Health (RO1 NS33070-03), and the Brain Tumor Society.1
Gordon, L. B., Nolan, S. C., Ksander, B. R., Knopf, P. M., & Harling‐Berg, C. J. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00077-0 · Cited by 30 · see citing works
CD8+ T Cell–Independent Tumor Regression Induced by Fc-OX40L and Therapeutic Vaccination in a Mouse Model of Glioma
Murphy, K. A., Erickson, J. R., Johnson, C. S., Seiler, C. E., Bedi, J., Hu, P., Pluhar, G. E., Epstein, A. L., & Ohlfest, J. R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301633 · Cited by 21 · see citing works
Self-citation
Integrating Costimulatory Agonists to Optimize Immune-Based Cancer Therapies
Pardee, A. D., Wesa, A. K., & Storkus, W. J. (2009) · Immunotherapy · doi:10.2217/1750743x.1.2.249 · Cited by 19 · see citing works

Flagged first, then by citations

1 of the 107 references couldn’t be matched to a known paper.

Sorted by citations

TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works
IL-33 drives the antitumor effects of dendritic cells via the induction of Tc9 cells
Liu, N., Jiang, Y., Chen, J., Nan, H., Zhao, Y., Chu, X., Wang, A., Wang, D., Qin, T., Gao, S., et al. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0166-0 · Cited by 35 · see citing works
TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas
Zheng, J., Wang, L., Zhao, S., Zhang, W., Chang, Y., Bosco, D. B., Huang, T., Dheer, A., Gao, S., Xu, S., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad214 · Cited by 31 · see citing works
Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis
Zhang, Z., Shen, X., Tan, Z., Mei, Y., Lu, T., Ji, Y., Cheng, S., Xu, Y., Wang, Z., Liu, X., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1053263 · Cited by 20 · see citing works
“CD8 T-cell have the potential to treat glioblastoma via CAR T-cell therapy (Murphy and Griffith, 2016).”
Background
The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy
Stepanenko, A. A., Sosnovtseva, A. O., Valikhov, M. P., Chernysheva, A. A., Abramova, O. V., Naumenko, V., & Chekhonin, V. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1326757 · Cited by 19 · see citing works
“…47 – 52, 58 – 60 ), although It is widely accepted that lymphocytes are key effector cells in the immune response to tumors, and that anti-cancer T cell-mediated immunity is key to improving survival outcomes, although the contribution of other immune cell types should not be underestimated (68).”
Background
Wilms Tumor 1-Associated Protein Expression Is Linked to a T-Cell-Inflamed Phenotype in Pancreatic Cancer
Xu, J.-L. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07620-7 · Cited by 12 · see citing works
“Besides, CD8+ T cells are superior antitumor effector T cells with strong cytolytic activity (CYT) against cancer cells [20, 21].”
Background
Immunoediting Dynamics in Glioblastoma: Implications for Immunotherapy Approaches
Amin, T., Hossain, A., Jerin, N., Mahmud, I., Rahman, M. A., Islam, S. M. R., & Islam, S. M. B. U. (2024) · Cancer Control · doi:10.1177/10732748241290067 · Cited by 7 · see citing works
“35 The BBB limits, but does not entirely prevent, immune cells from entering the brain.”
Background
Pediatric brain tumor patients display altered immune activation and reduced lymphopoiesis at the onset of disease
Rosichini, M., Baldo, G. D., Luca, C. D. D., Benini, F., Genah, S., Vinci, M., Cerimele, A., Coccetti, M., Flamini, S., Carsetti, R., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00755-y · Cited by 6 · see citing works
“Given that robust immune function is crucial in controlling cancer initiation and growth and for the success of anti-cancer therapies 22 , we reasoned that a better understanding of patient ’ s immune system status at the onset of the disease would guide in designing more…”
Theranostic Advancements in Brain Cancer: Promising Approaches for Emerging Therapy
Khanra, B., & Sarangi, M. K. (2026) · MedComm – Oncology · doi:10.1002/mog2.70080 · Cited by 1 · see citing works
Construction of Immune-related lncRNA Prognosis Models and Development Related Networks and Drugs in LGGPreprint
Zhang, X., He, X., Xiong, L., Xu, Y., Chen, W., Liu, X., Hu, X., & Xu, X. (2021) · Research Square · doi:10.21203/rs.3.rs-757554/v1
“The importance of cytotoxic CD8 T cells in mediating adaptive immune responses in various cancers [30] , including gliomas [31] , has been well documented.”
Advances in the role of mitochondrial homeostasis in hepatocellular carcinoma initiation and progression: Mechanisms and therapeutic opportunities
Xu, J., Meng, X., Gong, M., Sun, E., Sun, J., Hamdy, H., Shen, J., & Li, H. (2026) · Mitochondrial Communications · doi:10.1016/j.mitoco.2026.07.002

CD8+ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity
Pluhar, G. E., Pennell, C. A., & Olin, M. R. (2015) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2015013607 · Cited by 48 · see citing works
An Introduction to Immunotherapy in the Treatment of Brain Tumors
Komisarow, J. M., & Sampson, J. H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802420-1.00001-6 · Cited by 1 · see citing works
Antibody, T-cell and Dendritic Cell Immunotherapy for Malignant Brain Tumors
Chandramohan, V., Mitchell, D. A., Johnson, L. A., Sampson, J. H., & Bigner, D. D. (2013) · Future Oncology · doi:10.2217/fon.13.47 · Cited by 22 · see citing works
Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications
Yang, M.-Y., Zetler, P. M., Prins, R. M., Khan-Farooqi, H., & Liau, L. M. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.10.1481 · Cited by 29 · see citing works
Cellular immunity and immunotherapy of brain tumors
Robert, M. P. (2004) · Frontiers in bioscience · doi:10.2741/1465 · Cited by 38 · see citing works

Authors: Murphy, K., & Griffith, T.
Affiliations: University of Minnesota (US)
Corresponding author: Murphy, Katherine
ORCID: Griffith, Thomas
Venue: Cancers
Publisher: MDPI AG
Published: 2016-07-27
Volume: 8
Issue: 8
Pages: 71
ISSN: 2072-6694 (ISSN-L)
DOI: 10.3390/cancers8080071
PMC: PMC4999780
OpenAlex: W2501965469
Cited by: 11
References: 107
Citations by year: 2026: 2 · 2024: 3 · 2023: 2 · 2022: 1 · 2021: 1 · 2020: 1 · 2018: 1
FWCI: 0.04
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Cancers (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: National Cancer Institute (P30CA077598)
Topics: Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CD8+ T cells, high-grade glioma, brain tumor immunotherapy, tumor-specific T cell responses, immunological memory, salvage therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CD8 T Cell–Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks